RemeGen Co., Ltd.: Phase 3 study in Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations (540 participants)
RemeGen Co., Ltd.: Phase 3 study in Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations (540 participants). Its enrollment of 540 is top-decile (90th percentile of 8,879 records). Dated 44 days ago, it serves as a historical benchmark. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 540 · 90th percentile of 8,879 ClinicalTrialStartPulse records · 6.8x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | RemeGen Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations |
| NCT ID | NCT07829549 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations |
| Intervention types | drug |
| Target enrollment | 540 |
| Site countries | China |
| Posted | 2026-09-21 |
| Planned start | 2026-09-30 |
| Event | Newly registered study |
| Event date | 2026-09-21 |
| enrollment percentile | 90th of 8,879 (median 80, 6.8x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch RemeGen Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock RemeGen Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-21
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: RemeGen Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- RemeGen Co., Ltd.'s enrollment: 90th percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 540 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for RemeGen Co., Ltd.?
RemeGen Co., Ltd. registered a Phase 3 study (NCT07829549) in Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations targeting 540 participants, posted 2026-09-21.
How does RemeGen Co., Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 540 is 6.8x the median of 80 across 8,879 records. It is 44 days old, still within a typical 45-day follow-up window. Its Score of 75/100 puts it among the stronger signals in this feed.
RemeGen Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| RemeGen Co., Ltd. | NONUS | 540 | 90th | 2026-09-21 |
| Janssen Research & Development, LLC | US | 539 | 90th | 2026-11-03 |
| Genmab | US | 600 | 91st | 2026-11-03 |
| GlaxoSmithKline | NONUS | 610 | 91st | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor RemeGen Co., Ltd. and peer phase 3 records
Get new ClinicalTrialStartPulse records like RemeGen Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.